Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (58)
  • Open Access

    ARTICLE

    The lncRNA FEZF1-AS1 Promotes the Progression of Colorectal Cancer Through Regulating OTX1 and Targeting miR-30a-5p

    Jing Li*†, Lian-mei Zhao, Cong Zhang, Meng Li§, Bo Gao, Xu-hua Hu, Jian Cao, Gui-ying Wang

    Oncology Research, Vol.28, No.1, pp. 51-63, 2020, DOI:10.3727/096504019X15619783964700

    Abstract Long noncoding RNAs (lncRNAs) participate in and regulate the biological process of colorectal cancer (CRC) progression. Our previous research identified differentially expressed lncRNAs in 10 CRC tissues and 10 matched nontumor tissues by next-generation sequencing (NGS). In this study, we identified an lncRNA, FEZF1 antisense RNA 1 (FEZF1-AS1), and further explored its function and mechanism in CRC. We verified that FEZF1-AS1 is highly expressed in CRC tissues and cell lines. Through functional experiments, we found that reduced levels of FEZF1-AS1 significantly suppressed CRC cell migration, invasion, and proliferation and inhibited tumor growth in vivo. Mechanistically, we discovered that reduced levels… More >

  • Open Access

    ARTICLE

    The AKT/GSK3β-Mediated Slug Expression Contributes to Oxaliplatin Resistance in Colorectal Cancer via Upregulation of ERCC1

    Wei Wei*1, Xiao-Dong Ma†1, Guan-Min Jiang, Bin Shi§, Wen Zhong, Chun-Lei Sun§, Liang Zhao*, Yan-Jiao Hou*, Hao Wang*

    Oncology Research, Vol.28, No.4, pp. 423-438, 2020, DOI:10.3727/096504020X15877284857868

    Abstract Although oxaliplatin serves as one of the first-line drugs prescribed for treating colorectal cancer (CRC), the therapeutic effect is disappointing due to drug resistance. So far, the molecular mechanisms mediating oxaliplatin resistance remain unclear. In this study, we found the chemoresistance in oxaliplatin-resistant HCT116 cells (HCT116/OXA) was mediated by the upregulation of ERCC1 expression. In addition, the acquisition of resistance induced epithelial–mesenchymal transition (EMT) as well as the Slug overexpression. On the contrary, Slug silencing reversed the EMT phenotype, decreased ERCC1 expression, and ameliorated drug resistance. Further mechanistical studies revealed the enhanced Slug expression resulted from the activation of AKT/… More >

  • Open Access

    ERRATUM

    miR-107 Promotes Proliferation and Inhibits Apoptosis of Colon Cancer Cells by Targeting Prostate Apoptosis Response-4 (Par4)

    Fen Liu*†, Shaojun Liu*, Feiyan Ai*†, Decai Zhang*†, Zhiming Xiao*, Xinmin Nie, Yunfeng Fu§

    Oncology Research, Vol.28, No.5, pp. 553-557, 2020, DOI:10.3727/096504020X16032056440094

    Abstract Colorectal cancer (CRC) is one of the most common malignancies in the world, with a high incidence and a high mortality. However, the pathogenesis of CRC carcinogenesis is still unexplored. In this study, we investigated the role of miR-107 in the regulation of CRC cell proliferation and apoptosis. First, the expression of miR-107 was observed to be aberrantly increased in human CRC tumor tissues and cell lines when compared to the colonic control tissues and colon epithelial cells. Further study showed that the proliferative and apoptotic capacities of human CRC SW480 and LoVo cells were aberrantly regulated by miR-107. The… More >

  • Open Access

    ARTICLE

    PNN and KCNQ1OT1 Can Predict the Efficacy of Adjuvant Fluoropyrimidine-Based Chemotherapy in Colorectal Cancer Patients

    Andrea Lapucci*†1, Gabriele Perrone*†1, Antonello Di Paolo‡§, Cristina Napoli*†, Ida Landini*†, Giandomenico Roviello*†, Laura Calosi, Antonio Giuseppe Naccarato#, Alfredo Falcone#, Daniele Bani, Enrico Mini*†§2, Stefania Nobili*†§2,3

    Oncology Research, Vol.28, No.6, pp. 631-644, 2020, DOI:10.3727/096504020X16056983169118

    Abstract The benefit of adjuvant chemotherapy in the early stages of colorectal cancer (CRC) is still disappointing and the prediction of treatment outcome quite difficult. Recently, through a transcriptomic approach, we evidenced a role of PNN and KCNQ1OT1 gene expression in predicting response to fluoropyrimidine-based adjuvant chemotherapy in stage III CRC patients. Thus, the aim of this study was to validate in an independent cohort of stages II–III CRC patients our previous findings. PNN and KCNQ1OT1 mRNA expression levels were evaluated in 74 formalin-fixed paraffin-embedded tumor and matched normal mucosa samples obtained by stages II–III CRC patients treated with fluoropyrimidine-based adjuvant… More >

  • Open Access

    ARTICLE

    IL-24-Armed Oncolytic Vaccinia Virus Exerts Potent Antitumor Effects via Multiple Pathways in Colorectal Cancer

    Lili Deng*1, Xue Yang†1, Jun Fan*, Yuedi Ding*, Ying Peng*, Dong Xu*, Biao Huang*‡, Zhigang Hu

    Oncology Research, Vol.28, No.6, pp. 579-590, 2020, DOI:10.3727/096504020X15942028641011

    Abstract Colorectal cancer is an aggressive malignancy for which there are limited treatment options. Oncolytic vaccinia virus is being developed as a novel strategy for cancer therapy. Arming vaccinia virus with immunostimulatory cytokines can enhance the tumor cell-specific replication and antitumor efficacy. Interleukin-24 (IL-24) is an important immune mediator, as well as a broad-spectrum tumor suppressor. We constructed a targeted vaccinia virus of Guang9 strain harboring IL-24 (VG9-IL-24) to evaluate its antitumor effects. In vitro, VG9-IL-24 induced an increased number of apoptotic cells and blocked colorectal cancer cells in the G2 /M phase of the cell cycle. VG9-IL-24 induced apoptosis in… More >

  • Open Access

    RETRACTION

    Retraction notice to “miR-522-3p Promotes Tumorigenesis in Human Colorectal Cancer via Targeting Bloom Syndrome Protein” [Oncology Research 26(7) (2018) 1113–1121]

    Feng Shuai*, Bo Wang, Shuxiao Dong

    Oncology Research, Vol.28, No.9, pp. 977-977, 2020, DOI:10.3727/096504021X16297183140281

    Abstract This article has no abstract. More >

  • Open Access

    RETRACTION

    Retraction notice to “MicroRNA-204 Inhibits the Growth and Motility of Colorectal Cancer Cells by Downregulation of CXCL8” [Oncology Research 26(8) (2018) 1295–1305]

    Feng Shuai*, Bo Wang, Shuxiao Dong

    Oncology Research, Vol.28, No.9, pp. 975-975, 2020, DOI:10.3727/096504021X16297182567090

    Abstract This article has no abstract. More >

  • Open Access

    ERRATUM

    Long Noncoding RNA PlncRNA-1 Promotes Colorectal Cancer Cell Progression by Regulating the PI3K/Akt Signaling Pathway

    Wei Song*, Jia-Zhuan Mei, Mingzhi Zhang

    Oncology Research, Vol.28, No.9, pp. 971-972, 2020, DOI:10.3727/096504022X16414984936791

    Abstract Accumulating evidence has indicated that long noncoding RNA (lncRNA) PlncRNA-1 plays an important regulatory role in cancers. However, the expression and biological functions of PlncRNA-1 in colorectal cancer (CRC) are still unclear. In the present study, we determined the expression of PlncRNA-1 in CRC and explored the function of PlncRNA-1 on CRC cell progression. The results showed that PlncRNA-1 was significantly increased in CRC tissues and cell lines; high PlncRNA-1 expression was associated with depth of invasion, lymph node metastasis, and TNM stage of CRC patients. Kaplan–Meier curve analysis showed that patients with high PlncRNA-1 expression had a poor overall… More >

  • Open Access

    ARTICLE

    A Pilot Study of Silymarin as Supplementation to Reduce Toxicities in Metastatic Colorectal Cancer Patients Treated With First-Line FOLFIRI Plus Bevacizumab

    Tsung-Kun Chang*†, Tzu-Chieh Yin‡§, Wei-Chih Su*†, Hsiang-Lin Tsai, Ching-Wen Huang, Yen-Cheng Chen*, Ching-Chun Li*, Po-Jung Chen*, Cheng-Jen Ma, Kuo-Hsiang Chuang#, Tian-Lu Cheng**, Jaw-Yuan Wang*†¶††‡‡§§

    Oncology Research, Vol.28, No.7-8, pp. 801-809, 2020, DOI:10.3727/096504021X16218531628569

    Abstract Irinotecan, a topoisomerase inhibitor, is a common cytotoxic agent prescribed for metastatic colorectal cancer (mCRC) patients. Diarrhea is the most common adverse event (AE). The underlying mechanism of irinotecaninduced diarrhea is intestinal mucosal damage caused by SN-38 (active metabolite of irinotecan) hydrolyzed from SN-38G (inactive metabolite) by bacterial -glucuronidase ( G). According to an animal study, silymarin reduces the activity of bacterial G without impairing antitumor efficacy. We conducted a prospective openlabel pilot study to evaluate the effect of silymarin as supplementation in reducing toxicities of mCRC patients undergoing irinotecan-based chemotherapy. We enrolled and randomized 70 mCRC patients receiving first-line… More >

  • Open Access

    ARTICLE

    Prognostic Value of EGFR Expression for Patients With Stage III Colorectal Cancer Receiving Fluoropyrimidine Metronomic Maintenance Therapy After Radical Resection and Adjuvant Oxaliplatin-Based Chemotherapy

    Ching-Wen Huang*, Cheng-Jen Ma*†, Wei-Chih Su*, Yi-Ting Chen‡§, Hsiang-Lin Tsai, Yung-Sung Yeh*#, Tsung-Kun Chang*, Wen-Hung Hsu**††, Fang-Jung Yu**††, Jaw-Yuan Wang*¶‡‡§§¶¶##

    Oncology Research, Vol.28, No.7-8, pp. 701-714, 2020, DOI:10.3727/096504020X15986099915822

    Abstract This study evaluated the survival effects of metronomic maintenance therapy with oral fluoropyrimidine in patients with stage III colorectal cancer (CRC) according to epidermal growth factor receptor (EGFR) expression. We enrolled 197 patients with stage III CRC who had undergone radical resection and FOLFOX regimen adjuvant chemotherapy. The clinicopathological features and effects of metronomic maintenance therapy with oral capecitabine (daily dose of 850 mg/m2 , twice daily, on days 1–14 every 3 weeks for 6 months) on survival according to treatment group and EGFR expression were analyzed. By conducting an in vitro cell line study and in vivo study through… More >

Displaying 31-40 on page 4 of 58. Per Page